Home » Topics » BioWorld Science

BioWorld Science
RSS

Meiji Seika Pharma divulges histamine H4 receptor antagonists

Nov. 25, 2021

New PADI4 inhibitors synthesized at Gilead

Nov. 25, 2021

IL-17A/IL-17RA interaction modulators patented by Janssen Pharmaceutica

Nov. 25, 2021

New Bcl-2 inhibitors discovered at Prelude Therapeutics

Nov. 25, 2021

Pfizer describes new MAP4K1 inhibitors

Nov. 25, 2021

Adenosine A1R/A3R agonist AST-004 ameliorates brain infarction in an NHP model of stroke

Nov. 25, 2021

CDX-585, a novel bispecific antibody targeting ILT4 and PD-1 for cancer treatment

Nov. 25, 2021

Pridopidine has neuroprotective effects mediated by S1R in retinal ganglion cells of glaucoma models

Nov. 24, 2021

Restoring cellular miR-127-3p inhibits herpesvirus-induced tumorigenesis in vitro and in vivo

Nov. 24, 2021

New fully synthetic antibiotic class shows broad activity against multidrug-resistant bacteria

Nov. 24, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints
BioWorld
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...